HC Wainwright Reaffirms “Buy” Rating for Celcuity (NASDAQ:CELC)

HC Wainwright restated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report released on Friday,Benzinga reports. They currently have a $27.00 price target on the stock.

CELC has been the topic of a number of other research reports. Stifel Nicolaus upped their price target on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Lifesci Capital initiated coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Celcuity in a research report on Friday. Leerink Partners initiated coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average target price of $29.17.

Celcuity Stock Performance

Shares of Celcuity stock opened at $12.46 on Friday. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a twelve month low of $11.51 and a twelve month high of $22.19. The stock has a market cap of $461.39 million, a price-to-earnings ratio of -4.77 and a beta of 0.76. The company’s fifty day moving average is $15.15 and its 200 day moving average is $16.03.

Hedge Funds Weigh In On Celcuity

Institutional investors have recently made changes to their positions in the stock. Samlyn Capital LLC raised its holdings in shares of Celcuity by 92.4% in the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after acquiring an additional 637,190 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Celcuity in the 1st quarter worth about $3,545,000. Driehaus Capital Management LLC raised its holdings in shares of Celcuity by 62.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after acquiring an additional 78,525 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Celcuity in the 2nd quarter worth about $1,065,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Celcuity in the 2nd quarter worth about $888,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.